Investing in start-ups
Biocodex has invested in start-ups since 2016 and become a key player in the French biotech ecosystem. We focus mainly on companies developing innovative therapeutics with probiotics or microbial strains that are beneficial to health. With its long-term approach and industrial expertise, Biocodex is recognized as a valuable partner by CEOs, project owners and traditional investors, such as fund managers. Biocodex is always looking to support new meaningful projects.
Biocodex invests in MaaT Pharma
Biocodex acquired a stake in MaaT Pharma (Euronext: MAAT) in 2016. MaaT Pharma’s scientific teams exploit the potential of the microbiota by developing therapeutic products based on high richness and high diversity intestinal microbiota dedicated to cancer patients. Biocodex brings its 70 years of industrial expertise in strain culture, lyophilization and oral treatment and supports MaaT Pharma in the clinical development of its two drug candidates (MaaT013 in development for the treatment of graft-versus-host disease and MaaT033 in development for the treatment of patients receiving stem cell transplantation). MaaT Pharma relies on its powerful Artificial Intelligence-based discovery and analysis platform, gutPrint®, which supports the development of its product portfolio and its extension to broader indications, helping to identify new targets therapeutics, to evaluate drug candidates and to identify biomarkers for the management of pathologies involving the microbiota.
Biocodex invests in Exeliom Biosciences
Biocodex has invested in Exeliom Biosciences since 2018. This company’s mission is to develop a new class of medicines, Live Biotherapeutics, based on the growing understanding of the central role of the microbiota in the immune system. Exeliom Biosciences has developed a mono-strain approach using Faecalibacterium prausnitzii, which it believes could significantly improve the treatment of inflammatory bowel disease, such as Crohn’s disease or ulcerative colitis.
Biocodex invests in TargEDys
In 2019, Biocodex acquired a stake in TargEDys, a start-up aiming to act on metabolism balance. Among the company’s innovations, Probiosatys™ with a unique strain Hafnia alvei 4597. This technology is available to consumers through Biocodex’s Symbiosys® Satylia® product.
Biocodex invests in Kinnov Therapeutics
Biocodex has invested in Kinnov Therapeutics since 2018. Kinnov Therapeutics concentrates its research on the combination of cyproheptadine and prazosin, two molecules that work in synergy to treat addictions.
Kinnov Therapeutics is conducting a Phase II clinical trial to confirm the efficacy of combined cyproheptadine and prazosin in the treatment of alcohol addiction, a field lacking in medical solutions. This project has received funding from the European Union’s Horizon 2020 Research and Innovation program.
Biocodex invests in My Health
My Health was founded in 2017 by Raf Dybajlo. In 2021, the company published a clinical study in The Lancet Gastroenterology & Hepatology on the efficacy of My Health’s proprietary strains, MY01 & MY02, in the treatment of functional dyspepsia (unexplained stomach complaints). The company has been marketing a range of probiotic food supplements whose formulas have been rigorously selected based on scientific data, in response to growing consumer demand for solutions to digestive health, women’s health, brain health, joint health and immune system boosting.
Want to know more?
Partnering with Biocodex means cooperating in investments that create successful synergies. Biocodex aims to continue its development by focusing on our three pillars: the Microbiota Mission, Orphan drugs and Women's health. Biocodex business development team is constantly seeking for new opportunities.